PT-141 10mg

PT-141 (Bremelanotide) is a synthetic cyclic heptapeptide melanocortin receptor agonist with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH. It has a molecular weight of 1025.2 g/mol and CAS number 189691-06-3. PT-141 is a metabolite of Melanotan II, distinguished by the absence of the C-terminal amide group, which shifts its receptor selectivity profile.

Research demonstrates PT-141 acts primarily through the melanocortin-4 receptor (MC4R) in the central nervous system. Unlike PDE5 inhibitors that act peripherally on vascular smooth muscle, PT-141’s mechanism involves direct activation of hypothalamic neural pathways that modulate arousal responses. Studies show MC4R activation in the paraventricular nucleus and medial preoptic area of the hypothalamus initiates downstream signaling through oxytocin and dopamine pathways.

Preclinical research documents PT-141’s effects on sexual behavior paradigms in multiple animal models, with studies showing increased lordosis quotient in female rats and enhanced erectile response in male models, including those unresponsive to PDE5 inhibitors. This central mechanism of action has made it a subject of significant research interest.

Research also documents minimal effects on melanogenesis compared to Melanotan II, consistent with its reduced MC1R affinity, and limited cardiovascular effects at research-relevant doses.

Each vial contains 10mg of lyophilized PT-141 at greater than 99% purity, verified by independent HPLC and mass spectrometry.